Form 4: Edgewise Therapeutics Executive Sells Shares to Cover Tax Obligations

Behrad Derakhshan, Chief Business Officer of Edgewise Therapeutics, sold shares to cover tax obligations related to vesting Restricted Stock Units.

Summary

• On May 1, 2025, Behrad Derakhshan, the Chief Business Officer of Edgewise Therapeutics, exercised Restricted Stock Units (RSUs) and sold shares to cover statutory tax withholding obligations.
• A total of 5,209 shares were acquired through the vesting of RSUs.
• 1,691 shares were then sold on May 2, 2025, at an average price of $16.4542 per share to cover the tax obligations.
• Following these transactions, Derakhshan directly owns 20,355 shares of Edgewise Therapeutics.
• The sale was not a discretionary sale but rather a 'sell-to-cover' transaction to meet minimum statutory tax withholding requirements.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction (sell-to-cover) and doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, often related to compensation packages and tax obligations. These transactions are closely monitored by investors for insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units (RSUs) as a way to align management's interests with those of shareholders.
• Sell-to-cover transactions are a standard method for executives to meet their tax obligations when RSUs vest.
• The size and frequency of these transactions can vary widely depending on the company's size, industry, and compensation policies.
• Comparable companies in the biotechnology sector, such as BioMarin Pharmaceutical and Sarepta Therapeutics, also see regular Form 4 filings related to executive stock transactions.

Stakeholder Impact

• The sale of shares by an executive could have a minor, temporary impact on the stock price, but is unlikely to have a significant long-term effect.
• The transaction ensures the executive remains compliant with tax regulations.

Key Dates

Keywords

Form 4, Beneficial Ownership, Edgewise Therapeutics, EWTX, Behrad Derakhshan, Restricted Stock Units, RSUs, Sell-to-cover, Tax Withholding